Neuro Oncol

• 

  Publication Venue For

  • The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors..  21:1509-1518. 2019
  • Germline genetic landscape of pediatric central nervous system tumors..  21:1376-1388. 2019
  • Diet and risk of glioma: targets for prevention remain elusive..  21:832-833. 2019
  • Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines..  21:424-427. 2019
  • Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas..  21:440-450. 2019
  • Sex-specific gene and pathway modeling of inherited glioma risk..  21:71-82. 2019
  • Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool..  20:1652-1660. 2018
  • Genome-wide association analysis identifies a meningioma risk locus at 11p15.5..  20:1485-1493. 2018
  • Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma..  20:1547-1555. 2018
  • Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686..  20:1400-1410. 2018
  • Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma..  20:1411-1418. 2018
  • Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium..  20:873-884. 2018
  • Recent advances in intradural spinal tumors..  20:729-742. 2018
  • Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas..  20:632-641. 2018
  • Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143..  20:674-686. 2018
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy..  20:249-258. 2018
  • Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy..  20:259-267. 2018
  • Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report..  20:132-142. 2018
  • Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study..  19:1673-1682. 2017
  • Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis..  19:1391-1397. 2017
  • The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival..  19:1217-1227. 2017
  • Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study..  19:689-698. 2017
  • The radiosurgery fractionation quandary: single fraction or hypofractionation?.  19:ii38-ii49. 2017
  • Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults..  19:31-42. 2017
  • Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies..  18:1357-1366. 2016
  • Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation..  18:507-517. 2016
  • Isocitrate dehydrogenase mutations in gliomas..  18:16-26. 2016
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment..  17:1538-1539. 2015
  • Telomere maintenance and the etiology of adult glioma..  17:1445-1452. 2015
  • Vaccination strategies for neuro-oncology..  17 Suppl 7:vii15-vii25. 2015
  • Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials..  17:1188-1198. 2015
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial..  17:1148-1156. 2015
  • Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma..  17:1043-1045. 2015
  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study..  17:854-861. 2015
  • Response to "the epidemiology of glioma in adults: a 'state of the science' review"..  17:624-626. 2015
  • Immunotherapy advances for glioblastoma..  16:1441-1458. 2014
  • Epidermal growth factor receptor and variant III targeted immunotherapy..  16 Suppl 8:viii20-viii25. 2014
  • Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer..  16:1333-1340. 2014
  • Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma..  16:1129-1136. 2014
  • Identification and preliminary treatment data of xenografts representing tcga-defined subtypes..  16 Suppl 3:iii35. 2014
  • Idh1 mutations as a immunotherapeutic target for brain tumors..  16 Suppl 3:iii40. 2014
  • Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration..  16 Suppl 3:iii43. 2014
  • Oncolytic poliovirus immunotherapy of glioblastoma..  16 Suppl 3:iii41. 2014
  • Patient-derived xenografts mirror the proteomic profile of human glioblastoma: implications for personalized drug development..  16 Suppl 3:iii38. 2014
  • Prognostic marker analysis in pediatric posterior fossa ependymomas..  16 Suppl 3:iii27. 2014
  • Tert promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal..  16 Suppl 3:iii5-iii6. 2014
  • The epidemiology of glioma in adults: a "state of the science" review..  16:896-913. 2014
  • Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial"..  16:169-170. 2014
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study..  16:310-317. 2014
  • Imaging descriptors improve the predictive power of survival models for glioblastoma patients..  15:1389-1394. 2013
  • Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis..  15:1041-1047. 2013
  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study..  15:945-954. 2013
  • Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677..  15:936-944. 2013
  • Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology..  15:535-541. 2013
  • Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma..  15:242-250. 2013
  • Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study..  14:1404-1412. 2012
  • Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab..  13:660-668. 2011
  • Clinical trial end points for high-grade glioma: the evolving landscape..  13:353-361. 2011
  • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma..  13:324-333. 2011
  • Risk factors for oligodendroglial tumors: a pooled international study..  13:242-250. 2011
  • Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?.  13:3-13. 2011
  • Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab..  13:143-151. 2011
  • Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma..  12:1311-1317. 2010
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma..  12:1300-1310. 2010
  • HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea..  12:956-966. 2010
  • Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma..  12:871-881. 2010
  • Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses..  12:664-678. 2010
  • Assessing neurotoxicity from the low-dose radiation component of radiosurgery using magnetic resonance spectroscopy..  12:145-152. 2010
  • Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. 2016
  • RANDOMIZATION OF PATIENTS WITH GLIOBLASTOMA TO VACCINE SITE PRE-CONDITIONING WITH TETANUS-DIPHTHERIA TOXOID SYSTEMICALLY ENHANCES MIGRATION AND THERAPEUTIC EFFECT OF CYTOMEGALOVIRUS PP65-PULSED DENDRITIC CELL VACCINE IN A MIP-1α-DEPENDENT FASHION. 2014